These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 26759363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
    Chilton CH, Freeman J, Crowther GS, Todhunter SL, Wilcox MH.
    J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
    Chilton CH, Crowther GS, Todhunter SL, Nicholson S, Freeman J, Chesnel L, Wilcox MH.
    J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
    Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
    Chilton CH, Crowther GS, Todhunter SL, Ashwin H, Longshaw CM, Karas A, Wilcox MH.
    J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model.
    Chilton CH, Freeman J, Crowther GS, Todhunter SL, Nicholson S, Wilcox MH.
    J Antimicrob Chemother; 2012 Apr; 67(4):951-4. PubMed ID: 22279183
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
    Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
    [Abstract] [Full Text] [Related]

  • 19. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
    Baines SD, Saxton K, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.